Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M223Revenue $M6.1Net Margin (%)-638.2Z-Score14.6
Enterprise Value $M92.3EPS $-1.0Operating Margin %-645.5F-Score3
P/E(ttm))0Cash Flow Per Share $-0.9Pre-tax Margin (%)-638.2Higher ROA y-yY
Price/Book1.710-y EBITDA Growth Rate %0Quick Ratio12.7Cash flow > EarningsY
Price/Sales98.05-y EBITDA Growth Rate %0Current Ratio12.7Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-25.4Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-26.6Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M43.3ROI % (ttm)-27.5Gross Margin Increase y-yN

Gurus Latest Trades with CCXI

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found!

CCXI is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


CCXI: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Schall Thomas J.President and CEO 2014-05-01Sell27,726$5.59-8.94 view
Schall Thomas J.President and CEO 2014-04-29Sell32,274$5.38-5.39 view
Cappel Markus J.Chief Bus. Officer & Treasurer 2014-04-22Sell20,962$8.17-37.7 view
Schall Thomas J.President and CEO 2014-03-17Sell20,000$7.25-29.79 view
Schall Thomas J.President and CEO 2014-02-18Sell20,000$7.05-27.8 view
Parker Geoffrey M.Director 2013-12-06Buy20,000$5.15-1.17 view
BVF PARTNERS L P/IL10% Owner 2013-12-05Buy189,800$5.011.6 view
BVF PARTNERS L P/IL10% Owner 2013-11-06Buy136,066$4.923.46 view
BVF PARTNERS L P/IL10% Owner 2013-11-01Buy336,225$4.992 view
BVF PARTNERS L P/IL10% Owner 2013-10-09Buy1,289,354$5.34-4.68 view

Press Releases about CCXI :

    Quarterly/Annual Reports about CCXI:

    News about CCXI:

    Articles On GuruFocus.com
    New ipo recommended Sep 16 2012 

    More From Other Websites
    CHEMOCENTRYX, INC. Files SEC form 10-Q, Quarterly Report Aug 08 2014
    ChemoCentryx Announces Financial Results for the Second Quarter Ended June 30, 2014 Aug 05 2014
    CHEMOCENTRYX, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Aug 05 2014
    ChemoCentryx Announces Financial Results for the Second Quarter Ended June 30, 2014 Aug 05 2014
    Q2 2014 ChemoCentryx Inc Earnings Release - After Market Close Aug 05 2014
    ChemoCentryx to Hold Second Quarter 2014 Financial Results Conference Call on Tuesday, August 5,... Jul 23 2014
    ChemoCentryx to Hold Second Quarter 2014 Financial Results Conference Call on Tuesday, August 5,... Jul 23 2014
    ChemoCentryx's CCX168, an Orally Administered Complement C5a Receptor Inhibitor, Granted Orphan-Drug... Jun 03 2014
    ChemoCentryx receives orphan status for 5a receptor Jun 02 2014
    ChemoCentryx's Orally-Administered Complement 5a Receptor Inhibitor, CCX168, Shows Benefit in... Jun 02 2014
    CHEMOCENTRYX, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 28 2014
    CHEMOCENTRYX, INC. Financials May 20 2014
    CHEMOCENTRYX, INC. Files SEC form 10-Q, Quarterly Report May 09 2014
    ChemoCentryx's (CCXI) Tom Schall on Q1 2014 Results - Earnings Call Transcript May 08 2014
    CHEMOCENTRYX, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... May 08 2014
    ChemoCentryx reports Q1 EPS (27c), consensus (24c) May 08 2014
    Five Small Biotech Stocks Analysts Think Will Triple Apr 30 2014
    Why You Shouldn't Bet Against ChemoCentryx (CCXI) Stock Apr 11 2014
    ChemoCentryx Appoints Anne-Marie S. Duliege, M.D., M.S. to Chief Strategic Development Role and Head... Mar 27 2014
    ChemoCentryx appoints Dr. Anne-Marie Duliege to Chief of Strategic Development Mar 27 2014

    Add Notes, Comments or Ask Questions

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK
    Email Hide